Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00796445 · ClinicalTrials.gov registry record · Phase 3
A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor
A Phase 3 study, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,351
- Enrollment target
NCT00796445 is a Phase 3 study that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 1,351 participants.
The verdict
NCT00796445, a Phase 3 study, was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,351 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor. This Protocol Posting has been updated following Amendments 1 of the Protocol, March 2010. The impacted sections are outcome measures and entry criteria.
Interventions
- DRUG Placebo
- DRUG GSK 2132231A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,351 participants |
| Start Date | 2008-12-01 |
| Est. Completion | 2016-01-27 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00796445
The ClinicalTrials.gov registry entry for NCT00796445 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,351 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00796445 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00796445 about?
NCT00796445 is a clinical study titled "A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor". The purpose of this clinical trial is to evaluate the benefit of the immunotherapeutic product GSK 2132231A in preventing disease relapse when given to melanoma patients, after surgical removal of their tumor. This Protocol Posting has been updated following Amendments 1 of the Protocol, March 2010...
What is the current status of trial NCT00796445?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,351 participants. The study started on 2008-12-01. Estimated completion is 2016-01-27.
What interventions are being tested in trial NCT00796445?
The interventions under investigation include: Placebo (DRUG), GSK 2132231A (DRUG).
Who is sponsoring clinical trial NCT00796445?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.